GB202102396D0 - Molecular adjuvant - Google Patents
Molecular adjuvantInfo
- Publication number
- GB202102396D0 GB202102396D0 GBGB2102396.5A GB202102396A GB202102396D0 GB 202102396 D0 GB202102396 D0 GB 202102396D0 GB 202102396 A GB202102396 A GB 202102396A GB 202102396 D0 GB202102396 D0 GB 202102396D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- molecular adjuvant
- adjuvant
- molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002671 adjuvant Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102396.5A GB202102396D0 (en) | 2021-02-19 | 2021-02-19 | Molecular adjuvant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102396.5A GB202102396D0 (en) | 2021-02-19 | 2021-02-19 | Molecular adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202102396D0 true GB202102396D0 (en) | 2021-04-07 |
Family
ID=74871746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2102396.5A Ceased GB202102396D0 (en) | 2021-02-19 | 2021-02-19 | Molecular adjuvant |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202102396D0 (en) |
Citations (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1990003184A1 (en) | 1988-09-30 | 1990-04-05 | Bror Morein | Matrix with immunomodulating activity |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5047507A (en) | 1988-01-05 | 1991-09-10 | Research Corporation Technologies, Inc. | Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
| WO1996011711A1 (en) | 1994-10-12 | 1996-04-25 | Iscotec Ab | Saponin preparations and use thereof in iscoms |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5763202A (en) | 1988-06-03 | 1998-06-09 | Cytogen Corporation | Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells |
| US5877293A (en) | 1990-07-05 | 1999-03-02 | Celltech Therapeutics Limited | CDR grafted anti-CEA antibodies and their production |
| US5891996A (en) | 1972-09-17 | 1999-04-06 | Centro De Inmunologia Molecular | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| US5955075A (en) | 1992-03-11 | 1999-09-21 | Institute Of Virology, Slovak Academy Of Sciences | Method of inhibiting tumor growth using antibodies to MN protein |
| US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
| US6054297A (en) | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6129915A (en) | 1997-02-13 | 2000-10-10 | Schering Aktiengesellschaft | Epidermal growth factor receptor antibodies |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6159508A (en) | 1996-12-19 | 2000-12-12 | Adore-A-Pet, Ltd. | Xylitol-containing non-human foodstuff and method |
| WO2001009192A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
| US6217866B1 (en) | 1988-09-15 | 2001-04-17 | Rhone-Poulenc Rorer International (Holdings), Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6333405B1 (en) | 1996-10-31 | 2001-12-25 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6383487B1 (en) | 1990-03-16 | 2002-05-07 | Novartis Ag | Methods of treatment using CD25 binding molecules |
| US20020142359A1 (en) | 1996-05-04 | 2002-10-03 | Copley Clive Graham | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
| WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US20030077676A1 (en) | 2001-03-30 | 2003-04-24 | University Of California, Davis Technology Transfer Center | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US6590088B1 (en) | 1996-07-19 | 2003-07-08 | Human Genome Sciences, Inc. | CD33-like protein |
| WO2003064606A2 (en) | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US20040005647A1 (en) | 2001-03-30 | 2004-01-08 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2004004762A1 (en) | 2002-07-05 | 2004-01-15 | Isconova Ab | Iscom preparation and use thereof |
| US20040018198A1 (en) | 2001-12-03 | 2004-01-29 | Jean Gudas | Antibodies against carbonic anydrase IX (CA IX) tumor antigen |
| US6716966B1 (en) | 1999-08-18 | 2004-04-06 | Altarex Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| US6730300B2 (en) | 1996-03-20 | 2004-05-04 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| WO2004045512A2 (en) | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| US20040115193A1 (en) | 2002-03-01 | 2004-06-17 | Immunomedics, Inc. | Internalizing anti-CD-74 antibodies and methods of use |
| US6759045B2 (en) | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
| US20040166544A1 (en) | 2003-02-13 | 2004-08-26 | Morton Phillip A. | Antibodies to c-Met for the treatment of cancers |
| US6824993B2 (en) | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
| WO2005002620A1 (en) | 2003-07-07 | 2005-01-13 | Isconova Ab | Quil a fraction with low toxicity and use thereof |
| US20050031623A1 (en) | 2002-02-21 | 2005-02-10 | Jaromir Pastorek | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes |
| US20050037431A1 (en) | 2003-06-06 | 2005-02-17 | Genentech, Inc. | Methods and compositions for modulating HGF/Met |
| US20050053608A1 (en) | 2003-06-27 | 2005-03-10 | Richard Weber | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| US20060018899A1 (en) | 2004-07-22 | 2006-01-26 | Genentech, Inc. | HER2 antibody composition |
| US20060035907A1 (en) | 2004-02-23 | 2006-02-16 | Christensen James G | Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors |
| US20060083736A1 (en) | 2004-10-15 | 2006-04-20 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US20060088523A1 (en) | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulations |
| US20060134104A1 (en) | 2004-08-05 | 2006-06-22 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| US7129332B2 (en) | 2000-02-25 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| US7135301B2 (en) | 2001-06-21 | 2006-11-14 | Glycomimetics, Inc. | Detection and treatment of prostate cancer |
| US20060270594A1 (en) | 2005-03-25 | 2006-11-30 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| US7230084B2 (en) | 1998-05-20 | 2007-06-12 | Immunomedics, Inc. | Therapeutic using a bispecific antibody |
| US20070202044A1 (en) | 2002-10-08 | 2007-08-30 | Immunomedics, Inc. | Antibody therapy |
| US7300644B2 (en) | 1996-05-03 | 2007-11-27 | Immunomedics, Inc. | Targeted combination immunotherapy |
| US20070274991A1 (en) | 2006-03-31 | 2007-11-29 | Way Jeffrey C | Treatment of tumors expressing mutant EGF receptors |
| US20080057063A1 (en) | 2006-08-03 | 2008-03-06 | Julie Rinkenberger | Antibodies Directed to AlphaVBeta6 and Uses Thereof |
| US20080138898A1 (en) | 2006-10-31 | 2008-06-12 | Immunogen, Inc. | Methods for improving antibody production |
| US7462696B2 (en) | 2001-10-18 | 2008-12-09 | Bayer Pharmaceutical Corporation | Human antibodies that have MN binding and cell adhesion-neutralizing activity |
| US7465449B2 (en) | 2002-03-13 | 2008-12-16 | Biogen Idec Ma Inc. | Anti-αvβ6 antibodies |
| US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
| US7534431B2 (en) | 2003-01-31 | 2009-05-19 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| US20090162382A1 (en) | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US20090169550A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
| US7557189B2 (en) | 2002-11-07 | 2009-07-07 | Immunogen Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| US20090175860A1 (en) | 2006-03-30 | 2009-07-09 | Novartis Ag | Compositions and Methods of Use for Antibodies of c-Met |
| US20090175863A1 (en) | 2007-12-26 | 2009-07-09 | Elmar Kraus | Agents targeting cd138 and uses thereof |
| US20090187007A1 (en) | 2002-04-10 | 2009-07-23 | Lowman Henry B | Anti-her2 antibody variants |
| US20090185974A1 (en) | 2002-09-30 | 2009-07-23 | Immunomedics, Inc. | Chimeric, Human and Humanized Anti-Granulocyte Antibodies and Methods of Use |
| US20090202546A1 (en) | 2008-01-30 | 2009-08-13 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| US20090232810A1 (en) | 2007-12-26 | 2009-09-17 | Elmar Kraus | Immunoconjugates targeting cd138 and uses thereof |
| US20090252738A1 (en) | 2002-08-23 | 2009-10-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| US20100040629A1 (en) | 2003-08-04 | 2010-02-18 | Abgenix, Inc. | Antibodies to c-Met |
| US7674605B2 (en) | 2006-06-07 | 2010-03-09 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
| US7691375B2 (en) | 2004-07-02 | 2010-04-06 | Wilex Ag | Adjuvant theraphy of G250-expressing tumors |
| EP2175884A2 (en) | 2007-07-12 | 2010-04-21 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| US20100115639A1 (en) | 2007-07-12 | 2010-05-06 | Liliane Goetsch | Antibodies inhibiting c-met dimerization and uses thereof |
| US20100129369A1 (en) | 2008-11-21 | 2010-05-27 | Julian Davies | c-Met Antibodies |
| EP1827492B1 (en) | 2004-11-30 | 2010-08-11 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US7811564B2 (en) | 2003-01-28 | 2010-10-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
| WO2010128087A2 (en) | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US7875278B2 (en) | 2005-02-18 | 2011-01-25 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
| US20110028129A1 (en) | 2009-10-13 | 2011-02-03 | Hutchison James W | Proximity Triggered Profile-Based Wireless Matching |
| US7897351B2 (en) | 2001-03-29 | 2011-03-01 | Ramot At Tel-Aviv University Ltd. | Peptides and antibodies to MUC 1 proteins |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
| US20110064653A1 (en) | 2009-09-16 | 2011-03-17 | Immunomedics, Inc. | Class I Anti-CEA Antibodies and Uses Thereof |
| US7919273B2 (en) | 2008-07-21 | 2011-04-05 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| US20110097262A1 (en) | 2008-12-02 | 2011-04-28 | Liliane Goetsch | NOVEL ANTI-cMET ANTIBODY |
| US20110104176A1 (en) | 2009-10-30 | 2011-05-05 | Samsung Electronics Co., Ltd. | Antibody specifically binding to c-met and use thereof |
| US7943742B2 (en) | 2005-07-08 | 2011-05-17 | Biogen Idec Ma Inc. | Anti-αvβ6 antibodies and uses thereof |
| US20110123537A1 (en) | 2007-11-02 | 2011-05-26 | Wilex Ag | Binding epitopes for g250 antibody |
| US20110129481A1 (en) | 2009-11-27 | 2011-06-02 | Samsung Electronics Co., Ltd. | Antibody specifically binding to c-Met and methods of use |
| US7968685B2 (en) | 2004-11-09 | 2011-06-28 | Philogen S.P.A. | Antibodies against Tenascin-C |
| US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
| US20110171208A1 (en) | 2008-04-11 | 2011-07-14 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US7982017B2 (en) | 2007-12-18 | 2011-07-19 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
| US20110177095A1 (en) | 2009-12-16 | 2011-07-21 | Abbott Biotherapeutics Corporation | Anti-her2 antibodies and their uses |
| US20110206701A1 (en) | 2008-10-31 | 2011-08-25 | Daniel Afar | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| US20110217305A1 (en) | 2010-03-04 | 2011-09-08 | Symphogen A/S | Anti-her2 antibodies and compositions |
| US8021856B2 (en) | 1998-04-20 | 2011-09-20 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20110239316A1 (en) | 2008-12-02 | 2011-09-29 | Liliane Goetsch | ANTI-cMET ANTIBODY |
| WO2011161699A2 (en) | 2010-06-25 | 2011-12-29 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US20120052070A1 (en) | 2009-05-07 | 2012-03-01 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| US20120082664A1 (en) | 2006-08-14 | 2012-04-05 | Bernett Matthew J | Optimized antibodies that target cd19 |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US8609089B2 (en) | 2008-08-25 | 2013-12-17 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2014055648A1 (en) | 2012-10-02 | 2014-04-10 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US8735553B1 (en) | 2013-09-13 | 2014-05-27 | Beigene, Ltd. | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015042246A1 (en) | 2013-09-20 | 2015-03-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| WO2016007235A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| WO2016011160A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2016057667A1 (en) | 2014-10-10 | 2016-04-14 | Medimmune, Llc | Humanized anti-ox40 antibodies and uses thereof |
| WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2016083468A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| US20160304607A1 (en) | 2015-04-17 | 2016-10-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| WO2016166341A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
| WO2016179517A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| WO2016189124A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2016196792A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| WO2017130076A1 (en) | 2016-01-25 | 2017-08-03 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
| WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
-
2021
- 2021-02-19 GB GBGB2102396.5A patent/GB202102396D0/en not_active Ceased
Patent Citations (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891996A (en) | 1972-09-17 | 1999-04-06 | Centro De Inmunologia Molecular | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6013772A (en) | 1986-08-13 | 2000-01-11 | Bayer Corporation | Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5047507A (en) | 1988-01-05 | 1991-09-10 | Research Corporation Technologies, Inc. | Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen |
| US5763202A (en) | 1988-06-03 | 1998-06-09 | Cytogen Corporation | Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells |
| US6217866B1 (en) | 1988-09-15 | 2001-04-17 | Rhone-Poulenc Rorer International (Holdings), Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| WO1990003184A1 (en) | 1988-09-30 | 1990-04-05 | Bror Morein | Matrix with immunomodulating activity |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US6521230B1 (en) | 1990-03-16 | 2003-02-18 | Novartis Ag | CD25 binding molecules |
| US6383487B1 (en) | 1990-03-16 | 2002-05-07 | Novartis Ag | Methods of treatment using CD25 binding molecules |
| US5877293A (en) | 1990-07-05 | 1999-03-02 | Celltech Therapeutics Limited | CDR grafted anti-CEA antibodies and their production |
| US6054297A (en) | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
| US5955075A (en) | 1992-03-11 | 1999-09-21 | Institute Of Virology, Slovak Academy Of Sciences | Method of inhibiting tumor growth using antibodies to MN protein |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
| WO1996011711A1 (en) | 1994-10-12 | 1996-04-25 | Iscotec Ab | Saponin preparations and use thereof in iscoms |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6824993B2 (en) | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
| US20080069775A1 (en) | 1996-03-20 | 2008-03-20 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications |
| US6730300B2 (en) | 1996-03-20 | 2004-05-04 | Immunomedics, Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7300644B2 (en) | 1996-05-03 | 2007-11-27 | Immunomedics, Inc. | Targeted combination immunotherapy |
| US20020142359A1 (en) | 1996-05-04 | 2002-10-03 | Copley Clive Graham | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US7666425B1 (en) | 1996-05-06 | 2010-02-23 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6590088B1 (en) | 1996-07-19 | 2003-07-08 | Human Genome Sciences, Inc. | CD33-like protein |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6333405B1 (en) | 1996-10-31 | 2001-12-25 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6159508A (en) | 1996-12-19 | 2000-12-12 | Adore-A-Pet, Ltd. | Xylitol-containing non-human foodstuff and method |
| US6129915A (en) | 1997-02-13 | 2000-10-10 | Schering Aktiengesellschaft | Epidermal growth factor receptor antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US8021856B2 (en) | 1998-04-20 | 2011-09-20 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US7230084B2 (en) | 1998-05-20 | 2007-06-12 | Immunomedics, Inc. | Therapeutic using a bispecific antibody |
| WO2001009192A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| US6716966B1 (en) | 1999-08-18 | 2004-04-06 | Altarex Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| US7129332B2 (en) | 2000-02-25 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| US7550142B2 (en) | 2000-08-07 | 2009-06-23 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US6759045B2 (en) | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
| US7897351B2 (en) | 2001-03-29 | 2011-03-01 | Ramot At Tel-Aviv University Ltd. | Peptides and antibodies to MUC 1 proteins |
| US20030077676A1 (en) | 2001-03-30 | 2003-04-24 | University Of California, Davis Technology Transfer Center | Anti-MUC-1 single chain antibodies for tumor targeting |
| US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| US20040005647A1 (en) | 2001-03-30 | 2004-01-08 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7135301B2 (en) | 2001-06-21 | 2006-11-14 | Glycomimetics, Inc. | Detection and treatment of prostate cancer |
| US7462696B2 (en) | 2001-10-18 | 2008-12-09 | Bayer Pharmaceutical Corporation | Human antibodies that have MN binding and cell adhesion-neutralizing activity |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US7850971B2 (en) | 2001-10-23 | 2010-12-14 | Psma Development Company, Llc | PSMA antibodies and protein multimers |
| US20040033229A1 (en) | 2001-10-23 | 2004-02-19 | Maddon Paul J. | PSMA antibodies and protein multimers |
| US20080286284A1 (en) | 2001-10-23 | 2008-11-20 | Psma Development Company, Llc | Compositions of PSMA antibodies |
| US20040018198A1 (en) | 2001-12-03 | 2004-01-29 | Jean Gudas | Antibodies against carbonic anydrase IX (CA IX) tumor antigen |
| WO2003064606A2 (en) | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| US20080176258A1 (en) | 2002-02-21 | 2008-07-24 | Jaromir Pastorek | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IX's Coexpression with HER-2/neu/c-erbB-2, and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| US20050031623A1 (en) | 2002-02-21 | 2005-02-10 | Jaromir Pastorek | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes |
| US20080177046A1 (en) | 2002-02-21 | 2008-07-24 | Jaromir Pastorek | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IX's Coexpression with Her-2/neu/c-erbB-2, and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| US7816493B2 (en) | 2002-02-21 | 2010-10-19 | Institute Of Virology Of The Slovak Academy Of Sciences | Soluble form of carbonic anhydrase IX (S-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/NEU/C-ERBB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes |
| US20080176310A1 (en) | 2002-02-21 | 2008-07-24 | Jaromir Pastorek | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IX's Coexpression with HER-2/neu/c-erbB-2, and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| US20090162382A1 (en) | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US20040115193A1 (en) | 2002-03-01 | 2004-06-17 | Immunomedics, Inc. | Internalizing anti-CD-74 antibodies and methods of use |
| US7465449B2 (en) | 2002-03-13 | 2008-12-16 | Biogen Idec Ma Inc. | Anti-αvβ6 antibodies |
| US20110159014A1 (en) | 2002-04-10 | 2011-06-30 | Lowman Henry B | Anti-her2 antibody variants |
| US20090187007A1 (en) | 2002-04-10 | 2009-07-23 | Lowman Henry B | Anti-her2 antibody variants |
| US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
| WO2004004762A1 (en) | 2002-07-05 | 2004-01-15 | Isconova Ab | Iscom preparation and use thereof |
| US20090252738A1 (en) | 2002-08-23 | 2009-10-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| US20090185974A1 (en) | 2002-09-30 | 2009-07-23 | Immunomedics, Inc. | Chimeric, Human and Humanized Anti-Granulocyte Antibodies and Methods of Use |
| US20100221175A1 (en) | 2002-10-08 | 2010-09-02 | Immunomedics, Inc. | Antibody Therapy |
| US20070202044A1 (en) | 2002-10-08 | 2007-08-30 | Immunomedics, Inc. | Antibody therapy |
| US20090092598A1 (en) | 2002-10-08 | 2009-04-09 | Immunomedics, Inc. | Antibody Therapy |
| US20110189085A1 (en) | 2002-10-08 | 2011-08-04 | Immunomedics, Inc. | Antibody Therapy |
| US7557189B2 (en) | 2002-11-07 | 2009-07-07 | Immunogen Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| WO2004045512A2 (en) | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| US7811564B2 (en) | 2003-01-28 | 2010-10-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
| US7534431B2 (en) | 2003-01-31 | 2009-05-19 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| US20040166544A1 (en) | 2003-02-13 | 2004-08-26 | Morton Phillip A. | Antibodies to c-Met for the treatment of cancers |
| US20070129301A1 (en) | 2003-06-06 | 2007-06-07 | Kirchhofer Daniel K | Methods and compositions for modulating hgf/met |
| US20050037431A1 (en) | 2003-06-06 | 2005-02-17 | Genentech, Inc. | Methods and compositions for modulating HGF/Met |
| US20060035278A9 (en) | 2003-06-06 | 2006-02-16 | Genentech, Inc. | Methods and compositions for modulating HGF/Met |
| US20090156790A1 (en) | 2003-06-27 | 2009-06-18 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20050059087A1 (en) | 2003-06-27 | 2005-03-17 | Richard Weber | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20100111979A1 (en) | 2003-06-27 | 2010-05-06 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US7736644B2 (en) | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US7628986B2 (en) | 2003-06-27 | 2009-12-08 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20090155282A1 (en) | 2003-06-27 | 2009-06-18 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20090240038A1 (en) | 2003-06-27 | 2009-09-24 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20050053608A1 (en) | 2003-06-27 | 2005-03-10 | Richard Weber | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20090175887A1 (en) | 2003-06-27 | 2009-07-09 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| WO2005002620A1 (en) | 2003-07-07 | 2005-01-13 | Isconova Ab | Quil a fraction with low toxicity and use thereof |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US20100040629A1 (en) | 2003-08-04 | 2010-02-18 | Abgenix, Inc. | Antibodies to c-Met |
| US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| US20100016241A1 (en) | 2003-12-11 | 2010-01-21 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| US20070098707A1 (en) | 2003-12-11 | 2007-05-03 | Genentech, Inc. | Methods and Compositions for Inhibiting C-MET Dimerization and Activation |
| US20060035907A1 (en) | 2004-02-23 | 2006-02-16 | Christensen James G | Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors |
| WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7691375B2 (en) | 2004-07-02 | 2010-04-06 | Wilex Ag | Adjuvant theraphy of G250-expressing tumors |
| US20110117097A1 (en) | 2004-07-22 | 2011-05-19 | Genentech, Inc. | Her2 antibody composition |
| US20060018899A1 (en) | 2004-07-22 | 2006-01-26 | Genentech, Inc. | HER2 antibody composition |
| US20090285837A1 (en) | 2004-07-22 | 2009-11-19 | Genentech, Inc. | Her2 antibody composition |
| US20060134104A1 (en) | 2004-08-05 | 2006-06-22 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20070092520A1 (en) | 2004-08-05 | 2007-04-26 | Genentech, Inc. | Humanized Anti-CMET Antagonists |
| US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
| US20060083736A1 (en) | 2004-10-15 | 2006-04-20 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US20060088523A1 (en) | 2004-10-20 | 2006-04-27 | Genentech, Inc. | Antibody formulations |
| US7968685B2 (en) | 2004-11-09 | 2011-06-28 | Philogen S.P.A. | Antibodies against Tenascin-C |
| EP1827492B1 (en) | 2004-11-30 | 2010-08-11 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US7875278B2 (en) | 2005-02-18 | 2011-01-25 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| US20100028337A1 (en) | 2005-03-25 | 2010-02-04 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| US20060270594A1 (en) | 2005-03-25 | 2006-11-30 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US7943742B2 (en) | 2005-07-08 | 2011-05-17 | Biogen Idec Ma Inc. | Anti-αvβ6 antibodies and uses thereof |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| US20090175860A1 (en) | 2006-03-30 | 2009-07-09 | Novartis Ag | Compositions and Methods of Use for Antibodies of c-Met |
| US20090311803A1 (en) | 2006-03-31 | 2009-12-17 | Way Jeffrey C | Treatment Of Tumors Expressing Mutant EGF Receptors |
| US20070274991A1 (en) | 2006-03-31 | 2007-11-29 | Way Jeffrey C | Treatment of tumors expressing mutant EGF receptors |
| US7674605B2 (en) | 2006-06-07 | 2010-03-09 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
| US20080057063A1 (en) | 2006-08-03 | 2008-03-06 | Julie Rinkenberger | Antibodies Directed to AlphaVBeta6 and Uses Thereof |
| US20100330103A1 (en) | 2006-08-03 | 2010-12-30 | Astrazeneca Ab | Antibodies Directed to Alpha V Beta 6 And Uses Thereof |
| US20120082664A1 (en) | 2006-08-14 | 2012-04-05 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US20080138898A1 (en) | 2006-10-31 | 2008-06-12 | Immunogen, Inc. | Methods for improving antibody production |
| US20100115639A1 (en) | 2007-07-12 | 2010-05-06 | Liliane Goetsch | Antibodies inhibiting c-met dimerization and uses thereof |
| EP2175884A2 (en) | 2007-07-12 | 2010-04-21 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
| US20110123537A1 (en) | 2007-11-02 | 2011-05-26 | Wilex Ag | Binding epitopes for g250 antibody |
| US7982017B2 (en) | 2007-12-18 | 2011-07-19 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
| US20090169550A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Therapy of rituximab-refractory rheumatoid arthritis patients |
| US20090175863A1 (en) | 2007-12-26 | 2009-07-09 | Elmar Kraus | Agents targeting cd138 and uses thereof |
| US20090232810A1 (en) | 2007-12-26 | 2009-09-17 | Elmar Kraus | Immunoconjugates targeting cd138 and uses thereof |
| US20090202546A1 (en) | 2008-01-30 | 2009-08-13 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| US20110171208A1 (en) | 2008-04-11 | 2011-07-14 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US7919273B2 (en) | 2008-07-21 | 2011-04-05 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| US8609089B2 (en) | 2008-08-25 | 2013-12-17 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US20110206701A1 (en) | 2008-10-31 | 2011-08-25 | Daniel Afar | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| US20100129369A1 (en) | 2008-11-21 | 2010-05-27 | Julian Davies | c-Met Antibodies |
| US20110097262A1 (en) | 2008-12-02 | 2011-04-28 | Liliane Goetsch | NOVEL ANTI-cMET ANTIBODY |
| US20110239316A1 (en) | 2008-12-02 | 2011-09-29 | Liliane Goetsch | ANTI-cMET ANTIBODY |
| WO2010128087A2 (en) | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US20120052070A1 (en) | 2009-05-07 | 2012-03-01 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
| US20110064653A1 (en) | 2009-09-16 | 2011-03-17 | Immunomedics, Inc. | Class I Anti-CEA Antibodies and Uses Thereof |
| US20110028129A1 (en) | 2009-10-13 | 2011-02-03 | Hutchison James W | Proximity Triggered Profile-Based Wireless Matching |
| US20110104176A1 (en) | 2009-10-30 | 2011-05-05 | Samsung Electronics Co., Ltd. | Antibody specifically binding to c-met and use thereof |
| US20110129481A1 (en) | 2009-11-27 | 2011-06-02 | Samsung Electronics Co., Ltd. | Antibody specifically binding to c-Met and methods of use |
| US20110177095A1 (en) | 2009-12-16 | 2011-07-21 | Abbott Biotherapeutics Corporation | Anti-her2 antibodies and their uses |
| US20110217305A1 (en) | 2010-03-04 | 2011-09-08 | Symphogen A/S | Anti-her2 antibodies and compositions |
| WO2011161699A2 (en) | 2010-06-25 | 2011-12-29 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2014055648A1 (en) | 2012-10-02 | 2014-04-10 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US8735553B1 (en) | 2013-09-13 | 2014-05-27 | Beigene, Ltd. | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| US9834606B2 (en) | 2013-09-13 | 2017-12-05 | Beigene, Ltd | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| WO2015042246A1 (en) | 2013-09-20 | 2015-03-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| WO2016007235A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| WO2016011160A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2016057667A1 (en) | 2014-10-10 | 2016-04-14 | Medimmune, Llc | Humanized anti-ox40 antibodies and uses thereof |
| WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2016083468A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| WO2016166341A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
| US20160304607A1 (en) | 2015-04-17 | 2016-10-20 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| WO2016179517A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| WO2016189124A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2016196792A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| WO2017004016A1 (en) | 2015-06-29 | 2017-01-05 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| WO2017130076A1 (en) | 2016-01-25 | 2017-08-03 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
| WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
Non-Patent Citations (296)
| Title |
|---|
| "GenBank", Database accession no. NM_148902.1 |
| "Genbank", Database accession no. NP_001035120.1 |
| "NCBI Pubchem", Database accession no. 254741536 |
| "NCBI", Database accession no. AAG49451 |
| "UniProt", Database accession no. A0A0S4IUK8 |
| "uniprot", Database accession no. C90RF72 |
| "Uniprot", Database accession no. P04156-1 |
| ABDULLA NE. ET AL., BIODRUGS., vol. 26, no. 2, 1 April 2012 (2012-04-01), pages 71 - 82 |
| AL-KATIB AM. ET AL., CLIN CANCER RES., vol. 15, no. 12, 15 June 2009 (2009-06-15), pages 4038 - 45 |
| AM. J. HUM. GENET., vol. 49, no. 3, 1991, pages 555 - 565 |
| ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 |
| ANNU. REV. NEUROSCI., vol. 21, 1998, pages 309 - 345 |
| ARAI H. ET AL., JPN. CIRC. J., vol. 56, 1992, pages 1303 - 1307 |
| ARCE VARGAS ET AL., IMMUNITY, vol. 46, 18 April 2017 (2017-04-18), pages 1 - 10, Retrieved from the Internet <URL:http://dx.doi.ora/10.1016/i.immuni.2017.03.013> |
| ARCE VARGAS ET AL., IMMUNITY, vol. 46, 2017, pages 1 - 10 |
| ARCE-SILLAS, J. IMMUNOL. RES., 2016, pages 1720827 |
| ARGILES G. ET AL., FUTURE ONCOL., vol. 8, no. 4, April 2012 (2012-04-01), pages 373 - 89 |
| ATTIE T. ET AL., HUM. MOL. GENET., vol. 4, no. 2407- 15, 1995, pages 2409 |
| AURICCHIO A. ET AL., HUM. MOL. GENET., vol. 5, 1996, pages 355 - 357 |
| BAECKSTROM D. ET AL., J BIOL CHEM, vol. 266, 1991, pages 21537 - 21547 |
| BAREL M. ET AL., MOL. IMMUNOL., vol. 35, 1998, pages 1025 - 1031 |
| BARELLA ET AL., BIOCHEM. J., vol. 309, 1995, pages 773 - 779 |
| BARNETT T. ET AL., GENOMICS, vol. 3, 1988, pages 59 - 66 |
| BATISTA-DUHARTE ET AL., PHARMACOLOGICAL RESEARCH, vol. 129, 2018, pages 237 - 250 |
| BATISTA-DUHARTE ET AL., TOXICOL. LETT., vol. 10, no. 2, 2011, pages 97 - 105 |
| BATRA SK. ET AL., CELL GROWTH DIFFER, vol. 6, 1995, pages 1251 - 1259 |
| BAYRY ET AL., VIRUS DISEASE, vol. 25, no. 1, 2014, pages 18 - 25 |
| BEAUCHEMIN N. ET AL., MOL. CELL. BIOL., vol. 7, no. 9, 1987, pages 3221 - 3230 |
| BECK ET AL., J. MOL. BIOL., vol. 228, 1992, pages 433 - 441 |
| BECK ET AL., J. MOL. BIOL., vol. 25, no. 255, 1996, pages 1 - 13 |
| BENSON DM. ET AL., J CLIN ONCOL., vol. 30, no. 16, 1 June 2012 (2012-06-01), pages 2013 - 2015 |
| BERGSAGEL P.L. ET AL., J. IMMUNOL., vol. 148, no. 2, 1992, pages 1526 - 1531 |
| BERKOVA Z. ET AL., EXPERT OPIN INVESTIG DRUGS, vol. 19, no. 1, January 2010 (2010-01-01), pages 141 - 9 |
| BEROD ET AL., MICROBIOL. BIOTECHNOL., vol. 5, no. 2, 2012, pages 260 - 269 |
| BETTINI ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 21, no. 6, 2009, pages 612 - 618 |
| BIANCHI ET AL., HISTOL HISTOPATHOL., vol. 26, no. 7, July 2011 (2011-07-01), pages 941 - 51 |
| BLOOD, vol. 100, no. 8, 2002, pages 2662 - 2669 |
| BLUMBERG H. ET AL., CELL, vol. 104, 2001, pages 9 - 19 |
| BOLES K.S. ET AL., IMMUNOGENETICS, vol. 52, no. 3-4, 2001, pages 302 - 307 |
| BONAM ET AL., TRENDS PHARMACOL. SCI., 2017 |
| BOURGEOIS C. ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 82, 1997, pages 3116 - 3123 |
| BROADBRIDGE VT. ET AL., EXPERT REV ANTICANCER THER., vol. 12, no. 5, May 2012 (2012-05-01), pages 555 - 65 |
| BROWN, J. A. ET AL., J IMMUNOL., vol. I 70, 2003, pages 1257 - 1266 |
| BRUDNO, JN.KOCHENDORFER, JN., BLOOD, vol. 127, no. 26, 2016, pages 3321 - 3330 |
| BURCHELL J. ET AL., CANCER RES., vol. 47, 1987, pages 5476 - 5482 |
| CANCER RES., vol. 61, no. 15, 2001, pages 5857 - 5860 |
| CARDARELLI PM. ET AL., CANCERLMMUNOL IMMUNOTHER., vol. 59, no. 2, February 2010 (2010-02-01), pages 257 - 65 |
| CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357 |
| CAS, no. 7477202-00-9 |
| CELL, vol. 109, no. 3, 2002, pages 397 - 407 |
| CHAN,J.WATT, V.M., ONCOGENE, vol. 6, no. 6, 1991, pages 1057 - 1061 |
| CHMIELEWSKIABKEN, EXPERT OPIN BIOL THER, vol. 15, 2015, pages 1145 - 1154 |
| CICCODICOLA, A. ET AL., EMBO J., vol. 8, no. 7, 1989, pages 1987 - 1991 |
| CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
| CLARK H.F. ET AL., GENOME RES., vol. 13, no. 10, 2003, pages 2265 - 2270 |
| COUSSENS L. ET AL., SCIENCE, vol. 230, no. 4730, 1985, pages 1132 - 1139 |
| CUROTTO DE LAFAILLE ET AL., IMMUNITY, vol. 30, 2009, pages 626 - 635 |
| CUZZOCREA ET AL., FASEB J, vol. 21, 2007, pages 1 I 7 - 129 |
| CUZZOCREA ET AL., J IMMUNOL., vol. I 77, 2006, pages 631 - 641 |
| CUZZOCREA ET AL., J LEUKOC. BIOL., vol. 76, 2004, pages 933 - 940 |
| DAVIES ET AL., METHODS MOL. BIOL., vol. 1494, 2017, pages 107 - 125 |
| DAVIS ET AL., PROC. NATL. ACAD. SCI USA, vol. 98, no. 17, 2001, pages 9772 - 9777 |
| DAWOOD, S., EXPERT REV MOL DIAGN., vol. 10, no. 5, July 2010 (2010-07-01), pages 581 - 90 |
| DE SAUVAGE F.J. ET AL., J. BIOL. CHEM., vol. 266, no. 11, 1991, pages 17912 - 17918 |
| DE SIMONE ET AL., IMMUNITY, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1135 - 1147 |
| DEAN M. ET AL., NATURE, vol. 318, no. 6044, 1985, pages 385 - 388 |
| DHOMEN NS. ET AL., CRIT REV ONCOG., vol. 17, no. 1, 2012, pages 31 - 50 |
| DICKINSON D.P. ET AL., INVEST OPHTHALMOL. VIS. SCI., vol. 36, no. 10, 1995, pages 2020 - 2031 |
| DICKSON,G. ET AL., CELL, vol. 50, no. 7, 1987, pages 1119 - 1130 |
| DIJOSEPH JF., CANCER IMMUNOL IMMUNOTHER., vol. 54, no. 1, January 2005 (2005-01-01), pages 11 - 24 |
| DOBNER ET AL., EUR. J. IMMUNOL., vol. 22, no. 6, 1992, pages 2795 - 2799 |
| DONG H. ET AL., NAT. MED., vol. 8, 2002, pages 793 - 800 |
| DRUG DISCOV TODAY, vol. 20, no. 9, September 2015 (2015-09-01), pages 1127 - 34 |
| DUMOUTIER L. ET AL., J. IMMUNOL., vol. 167, 2001, pages 3545 - 3549 |
| DURKOP H. ET AL., CELL, vol. 68, no. 3, 1992, pages 421 - 427 |
| EHSANI A. ET AL., GENOMICS, vol. 15, 1993, pages 426 - 429 |
| ELLERMAN, METHODS, vol. 154, 1 February 2019 (2019-02-01), pages 102 - 117 |
| ELSHOURBAGY N.A. ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 3817 - 3820 |
| ELWOOD P.C. ET AL., J. BIOL. CHEM., vol. 264, no. 25, 1989, pages 14893 - 14901 |
| FEIGELSTOCK D. ET AL., J. VIROL., vol. 72, no. 8, 1998, pages 6621 - 6628 |
| FEILD, J.A. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 266, no. 3, 1999, pages 593 - 602 |
| FIELDING A., HAEMATOLOGICA, vol. 95, no. 1, January 2010 (2010-01-01), pages 8 - 12 |
| FISHER ET AL., IMMUN. INFLAMM. DIS., vol. 5, no. 1, 2016, pages 16 - 28 |
| FRATTA E. ET AL., MOL ONCOL., vol. 5, no. 2, April 2011 (2011-04-01), pages 164 - 82 |
| FUCHS S. ET AL., MOL. MED., vol. 7, 2001, pages 115 - 124 |
| FULCINITI M. ET AL., BLOOD, vol. 114, no. 2, 9 July 2009 (2009-07-09), pages 371 - 379 |
| GAO J. ET AL.: "International Joint Cancer Institute and Changhai Hospital Cancer Cent: HMTI-Fc Ab", BMB REP., vol. 42, no. 10, 31 October 2009 (2009-10-31), pages 636 - 41 |
| GARCON ET AL., HUM.VAC. & IMM., vol. 13, no. 1, 2017, pages 19 - 33 |
| GARY S.C. ET AL., GENE, vol. 256, 2000, pages 139 - 147 |
| GAUGITSCH, H.W., J. BIOL. CHEM., vol. 267, no. 16, 1992, pages 11267 - 11273 |
| GENDLER S.J. ET AL., J. BIOL. CHEM., vol. 265, no. 25, 1990, pages 15286 - 15293 |
| GENOMICS, vol. 62, no. 2, 1999, pages 281 - 284 |
| GLYNNE-JONES ET AL., INT J CANCER., vol. 94, no. 2, 15 October 2001 (2001-10-15), pages 178 - 84 |
| GOLDENBERG DM. ET AL., EXPERT REV ANTICANCER THER., vol. 6, no. 10, 2006, pages 1341 - 53 |
| GOLDENBERG DM. ET AL., LEUK LYMPHOMA., vol. 51, no. 5, May 2010 (2010-05-01), pages 747 - 55 |
| GOODWIN R.G. ET AL., CELL, vol. 73, no. 3, 1993, pages 447 - 456 |
| GU Z. ET AL., ONCOGENE, vol. 19, 2000, pages 1288 - 1296 |
| GUPTA ET AL., CELL, vol. 127, no. 4, 2006, pages 679 - 95 |
| GUPTA P. ET AL.: "BMC Biotechnol.", vol. 10, 7 October 2010, STANFORD UNIVERSITY MEDICAL CENTER, pages: 72 |
| HAENDLER B. ET AL., J. CARDIOVASC. PHARMACOL., vol. 20, 1992, pages s1 - S4 |
| HAGLUND C. ET AL., BR J CANCER, vol. 60, 1989, pages 845 - 851 |
| HAMANN P., EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103 |
| HARTMANN, J. ET AL., EMBO MOL. MED., vol. 9, no. 9, 2017, pages 1183 - 1197 |
| HASHIMOTO, IMMUNOGENETICS, vol. 40, no. 4, 1994, pages 287 - 295 |
| HE ET AL., HUM.VAC. & IMM., vol. 11, no. 2, 2015, pages 477 - 488 |
| HEIDER KH. ET AL., BLOOD, vol. 118, no. 15, 13 October 2011 (2011-10-13), pages 4159 - 68 |
| HERBST R. ET AL., J PHARMACOL EXP THER., vol. 335, no. 1, October 2010 (2010-10-01), pages 213 - 22 |
| HOFSTRA R.M.W. ET AL., EUR. J. HUM. GENET., vol. 5, 1997, pages 180 - 185 |
| HOFSTRA R.M.W. ET AL., NAT. GENET., vol. 12, 1996, pages 445 - 447 |
| HOOGENBOOM,H.R. ET AL., J IMMUNOL, vol. 144, 1990, pages 3211 - 3217 |
| HORIE ET AL., GENOMICS, vol. 67, 2000, pages 146 - 152 |
| HOU S. ET AL., MOL CANCER THER, November 2011 (2011-11-01), pages 10 |
| HUBERT, R.S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 96, no. 20, 1999, pages 11531 - 11536 |
| IMMUNOGENETICS, vol. 54, no. 2, 2002, pages 87 - 95 |
| INT. J. MOL. SCI., vol. 17, no. 7, July 2016 (2016-07-01), pages 1151 |
| INT. REV. CYTOL., vol. 196, 2000, pages 177 - 244 |
| ISRAELI R.S. ET AL., CANCER RES., vol. 53, no. 2, 1993, pages 227 - 230 |
| IVANOV PK. ET AL., BIOTECHNOL J., vol. 2, no. 7, July 2007 (2007-07-01), pages 863 - 70 |
| J. BIOL. CHEM., vol. 270, no. 37, 1995, pages 21984 - 21990 |
| J. BIOL. CHEM., vol. 276, no. 29, 2001, pages 27371 - 27375 |
| J. BIOL. CHEM., vol. 278, no. 33, 2003, pages 30813 - 30820 |
| JAGANNATH S. ET AL., POSTER ASH #3060, 2010 |
| JIAO Y. ET AL., MOL BIOTECHNOL., vol. 31, no. 1, September 2005 (2005-09-01), pages 41 - 54 |
| JIN-HUA P. ET AL., GENOMICS, vol. 45, no. 2, 1997, pages 412 - 415 |
| KASAHARA ET AL., IMMUNOGENETICS, vol. 30, no. 1, 1989, pages 411 - 413 |
| KATO, K. ET AL., INT. J. UROL., vol. 10, 2003, pages 439 - 444 |
| KEENAN ET AL., GASTROENTEROLOGY, vol. 146, no. 7, 2014, pages 1784 - 1794 |
| KENNETT RH. ET AL., CURR OPIN MOL THER., vol. 5, no. 1, February 2003 (2003-02-01), pages 70 - 5 |
| KING K.W., BIOCHIM. BIOPHYS. ACTA, vol. 1445, no. 3, 1999, pages 257 - 270 |
| KLAGES ET AL., CANCER RES., vol. 70, no. 20, 2010, pages 7788 - 7799 |
| KNAPPIK, A. ET AL., J MOL BIOL, vol. 296, no. 1, February 2000 (2000-02-01), pages 57 - 86 |
| KO ET AL., J EXP. MED., vol. 7, 2005, pages 885 - 891 |
| KO ET AL., THER ADV MED ONCOL, vol. 10, 2018, pages 1 - 11 |
| KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
| KORISTKA ET AL., ONCOIMMUNOLOGY, vol. 4, no. 3, March 2015 (2015-03-01), pages e994441 |
| KUDO,J. ET AL., NUCLEIC ACIDS RES., vol. 13, no. 24, 1985, pages 8827 - 8841 |
| KUGLER M. ET AL., PROTEIN ENG DES SEL., vol. 22, no. 3, March 2009 (2009-03-01), pages 135 - 47 |
| KUHNS J.J. ET AL., J. BIOL. CHEM., vol. 274, no. 27, 1999, pages 19465 - 19472 |
| KUKOWSKA-LATALLO,J.F. ET AL., GENES DEV., vol. 4, no. 8, 1990, pages 1288 - 1303 |
| KUZIEL W.A. ET AL., J. INVEST. DERMATOL., vol. 94, no. 6, 1990, pages 27S - 32S |
| LAABI Y. ET AL., NUCLEIC ACIDS RES., vol. 22, no. 7, 1994, pages 1147 - 1154 |
| LAB. INVEST., vol. 82, no. 11, 2002, pages 1573 - 1582 |
| LAMBERT J., CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549 |
| LANG P. ET AL.: "Blood", vol. 103, 15 May 2004, UNIVERSITY OF TUBINGEN, pages: 3982 - 5 |
| LARHAMMAR, J. BIOL. CHEM., vol. 260, no. 26, 1985, pages 14111 - 14119 |
| LE ET AL., FEBS LETT., vol. 418, no. 1-2, 1997, pages 195 - 199 |
| LEE JW. ET AL., CLIN CANCER RES., vol. 16, no. 9, 1 May 2010 (2010-05-01), pages 2562 - 2570 |
| LIANG ET AL., CANCER RES., vol. 60, 2000, pages 4907 - 12 |
| LIM SH., AM J BLOOD RES., vol. 2, no. 1, 2012, pages 29 - 35 |
| LIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, no. 30I, 2008, pages I-6 |
| LIU HQ. ET AL.: "Union Stem Cell &Gene Engineering", XI BAO YU FEN ZI MIAN YI XUE ZA ZHI., vol. 26, no. 5, May 2010 (2010-05-01), pages 456 - 8 |
| LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459 |
| LU RM. ET AL., BIOMATERIALS, vol. 32, no. 12, April 2011 (2011-04-01), pages 3265 - 74 |
| MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
| MENETRIER-CAUX, C. ET AL., TARG ONCOL, vol. 7, 2012, pages 15 - 28 |
| MILLER ET AL., JOUR. OF IMMUNOLOGY, vol. 170, 2003, pages 4854 - 4861 |
| MIURA ET AL., GENOMICS, vol. 38, no. 3, 1996, pages 299 - 304 |
| MOFFETT S. ET AL., HYBRIDOMA (LARCHMT)., vol. 26, no. 6, December 2007 (2007-12-01), pages 363 - 72 |
| MOORE M. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 84, 1987, pages 9194 - 9198 |
| MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
| MUNGALL A.J. ET AL., NATURE, vol. 425, 2003, pages 805 - 811 |
| NAGASE T. ET AL., DNA RES., vol. 7, no. 2, 2000, pages 143 - 150 |
| NAKAYAMA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 277, no. 1, 2000, pages 124 - 127 |
| NARUSE ET AL., TISSUE ANTIGENS, vol. 59, 2002, pages 512 - 519 |
| NATURE, vol. 395, no. 6699, 1998, pages 288 - 291 |
| NIEDZWIECKI ET AL., J.IMMUN.R., vol. 2018 |
| NIGHTINGALE G. ET AL., ANN PHARMACOTHER., vol. 45, no. 10, October 2011 (2011-10-01), pages 1248 - 55 |
| NOCENTINI, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 6216 - 622 |
| NOMI, T. ET AL., CLIN. CANCER RES., vol. 13, 2007, pages I 757 - 2157 |
| O'BRYAN J.P. ET AL., MOL. CELL. BIOL., vol. 11, no. 10, 1991, pages 5016 - 5031 |
| O'CONNELL FP. ET AL., AM J CLIN PATHOL., vol. 121, no. 2, February 2004 (2004-02-01), pages 254 - 63 |
| OFFNER S. ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 54, no. 5, May 2005 (2005-05-01), pages 431 - 45 |
| OFLAZOGLU, E. ET AL., CLIN CANCER RES., vol. 14, no. 19, 1 October 2008 (2008-10-01), pages 6171 - 80 |
| OHMAN L. ET AL.: "Tumour Biol.", vol. 23, March 2002, UPPSALA UNIVERSITY, pages: 61 - 9 |
| OKAMOTO Y. ET AL., BIOL. CHEM., vol. 272, 1997, pages 21589 - 21596 |
| OKAZAKIHONJO, INT. IMMUNOL., vol. 19, 2007, pages 813 - 824 |
| ONCOGENE, vol. 10, no. 5, 1995, pages 897 - 905 |
| ONCOGENE, vol. 14 10, no. 11, 1997, pages 1377 - 1382 |
| OWEIDA ET AL., CLIN CANCER RES, 24 July 2018 (2018-07-24) |
| PACCHIANA G. ET AL., J BIOL CHEM., vol. 285, no. 46, 12 November 2010 (2010-11-12), pages 36149 - 57 |
| PARK S.K., J. BIOCHEM., vol. 119, no. 2, 1996, pages 235 - 239 |
| PARRISH-NOVAK J. ET AL., J. BIOL. CHEM., vol. 277, no. 22, 2002, pages 47517 - 47523 |
| PARRY R. ET AL., CANCER RES., vol. 65, no. 18, 15 September 2005 (2005-09-15), pages 8397 - 405 |
| PASTOREK J. ET AL., ONCOGENE, vol. 9, no. 10, 1994, pages 2877 - 2888 |
| PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212 |
| PEDRETTI M. ET AL., LUNG CANCER., vol. 64, no. 1, April 2009 (2009-04-01), pages 28 - 33 |
| PERE ET AL., ONCOIMMUNOLOGY, vol. 1, no. 3, 2012, pages 326 - 333 |
| PETRUL HM. ET AL., MOL CANCER THER., vol. 11, no. 2, February 2012 (2012-02-01), pages 340 - 9 |
| PINGAULT V. ET AL., HUM. GENET., vol. 111, 2002, pages 198 - 206 |
| PLETNEV S. ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 12617 - 12624 |
| PLOWMAN,G.D. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 87, no. 13, 1990, pages 4905 - 4909 |
| PREUD'HOMME, CLIN. EXP. 5 IMMUNOL., vol. 90, no. 1, 1992, pages 141 - 146 |
| PROC. NATL. ACAD. SCI. U.S.A., vol. 10, no. 1, 1996, pages 136 - 140 |
| PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 7, 2003, pages 4126 - 4131 |
| PUFFENBERGER E.G. ET AL., CELL, vol. 79, 1994, pages 1257 - 1266 |
| RACK ET AL., JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 106, no. 5, 2014 |
| RAMAKRISHNAN MS. ET AL., MABS, vol. 1, no. 1, January 2009 (2009-01-01), pages 41 - 8 |
| RAZA A. ET AL., LEUK LYMPHOMA., vol. 50, no. 8, August 2009 (2009-08-01), pages 1336 - 44 |
| RECH AJ. ET AL., ANN N YACAD SCI., vol. 1174, September 2009 (2009-09-01), pages 99 - 106 |
| REITER R.E. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 95, 1998, pages 1735 - 1740 |
| RIUS C. ET AL., BLOOD, vol. 92, no. 12, 1998, pages 4677 - 4690 |
| RIVERA F. ET AL., EXPERT OPIN BIOL THER., vol. 9, no. 5, May 2009 (2009-05-01), pages 667 - 74 |
| ROBINSON ET AL., BLOOD, 2018 |
| ROGUSKA, M.A. ET AL., PROC NATL ACAD SCI USA, vol. 91, February 1994 (1994-02-01), pages 969 - 973 |
| RONSIN C. ET AL., ONCOGENE, vol. 8, no. 5, 1993, pages 1195 - 1202 |
| ROSS ET AL., CANCER RES., vol. 62, 2002, pages 2546 - 2553 |
| SAKAGUCHI ET AL., EMBO J., vol. 7, no. 11, 1988, pages 3457 - 3464 |
| SAKAMOTO A.YANAGISAWA M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 179, no. 3, 1991, pages 1455 - 1463 |
| SCANLAN,M.J., PROC. NATL. ACAD. SCI. U.S.A., vol. 91, no. 12, 1994, pages 5657 - 5661 |
| SCHIJNS ET AL., EXP.REV.VAC., vol. 10, no. 4, 2011, pages 539 - 550 |
| SCHNEIDER,C. ET AL., J BIOL CHEM, vol. 257, 1982, pages 8516 - 8522 |
| SCHOEBERL B. ET AL., CANCER RES., vol. 70, no. 6, 15 March 2010 (2010-03-15), pages 2485 - 2494 |
| SCHWARTZ-ALBIEZ R. ET AL., J. IMMUNOL., vol. 140, no. 3, 1988, pages 2797 - 2800 |
| SEMBA K. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 6497 - 6501 |
| SERVENIUS ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 8759 - 8766 |
| SHEIKH F. ET AL., J. IMMUNOL., vol. 172, 2004, pages 2006 - 2010 |
| SHEPPARD D.J. ET AL., BIOL. CHEM., vol. 265, no. 20, 1990, pages 11502 - 11507 |
| SHEVACH ET AL., NAT. REV. IMMUNOL., vol. 6, 2006, pages 613 - 618 |
| SICA GL. ET AL., IMMUNITY, vol. 18, no. 6, June 2003 (2003-06-01), pages 849 - 61 |
| SINHA S.K. ET AL., J. IMMUNOL., vol. 150, 1993, pages 5311 - 5320 |
| SIRI A. ET AL., NUCLEIC ACIDS RES., vol. 19, no. 3, 1991, pages 525 - 531 |
| SKOETZ N. ET AL., COCHRANE DATABASE SYST REV., 15 February 2012 (2012-02-15), pages 2 |
| SMITH SV ET AL., CURR OPIN MOL THER., vol. 7, no. 4, August 2005 (2005-08-01), pages 394 - 401 |
| SMITH, L.M., AACR 2010 ANNUAL MEETING, 2010 |
| SORENSEN AL. ET AL., GLYCOBIOLOGY, vol. 16, no. 2, 2006, pages 96 - 107 |
| STAMENKOVIC I. ET AL., NATURE, vol. 345, no. 6270, 1990, pages 74 - 77 |
| STRAUSBERG ET AL., PROC. NATL. ACAD. SCI USA, vol. 99, 2002, pages 16899 - 16903 |
| STRAUSBERG R.L. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 99, no. 26, 2002, pages 16899 - 16903 |
| STROME, S. E. ET AL., CANCER RES., vol. 63, 2003, pages 6501 - 6505 |
| SUKUMAR ET AL., CANCER RES., 2017 |
| SUKUMAR ET AL., CANCER RESEARCH, vol. 77, 2017 |
| SUSINI C. ET AL., ANN ONCOL., vol. 17, no. 12, December 2006 (2006-12-01), pages 1733 - 42 |
| SUTHERLAND, D.R. ET AL., PROC NATL ACAD SCI USA, vol. 78, no. 7, 1981, pages 4515 - 4519 |
| SUZUKI H. ET AL., ANN N YACAD SCI., vol. 1258, July 2012 (2012-07-01), pages 65 - 70 |
| SUZUKI S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 83, no. 22, 1986, pages 8614 - 8618 |
| SVENSSON P.J. ET AL., HUM. GENET., vol. 103, 1998, pages 145 - 148 |
| SWIERCZ J.M. ET AL., J. CELL BIOL., vol. 165, no. 869- 15, 2004, pages 880 |
| SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614 |
| TANAKA, A. ET AL., CELL RES., vol. 27, no. 1, January 2017 (2017-01-01), pages 109 - 118 |
| TAWARAGI Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 150, 1988, pages 89 - 96 |
| TAYLOR KM. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1611, no. 1-2, 1 April 2003 (2003-04-01), pages 16 - 30 |
| TEDDER T.F. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, no. 1, 1988, pages 208 - 212 |
| TEDDER TF. ET AL., J. IMMUNOL., vol. 143, no. 2, 1989, pages 712 - 7 |
| TEN DIJKE,P. ET AL., SCIENCE, vol. 264, no. 5155, 1994, pages 101 - 104 |
| TERABE ET AL., J EXP MED, vol. 202, 2005, pages 1627 - 33 |
| TERABE ET AL., NAT IMMUNOL, vol. 1, 2000, pages 515 - 20 |
| THIE H. ET AL., PLOS ONE, vol. 6, no. 1, 14 January 2011 (2011-01-14), pages e15921 |
| THOMPSON, J.S. ET AL., SCIENCE, vol. 293, no. 5537, 2001, pages 2108 - 2111 |
| THOMPSON, R.H. ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 3381 - 2337 |
| TIBERGHIEN, A.C., TETRAHEDRON LETTERS, vol. 58, no. 46, 2017, pages 4363 - 4366 |
| TIGUE NJBAMBER LANDREWS J ET AL.: "MED11873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential", ONCOIMMUNOLOGY, vol. 6, no. 3, 2017, pages e1280645 |
| TING J. ET AL., DNA, vol. 7, no. 4, 1988, pages 275 - 286 |
| TOLCHER AW ET AL., J CLIN ONCOL., vol. 21, no. 2, 15 January 2003 (2003-01-15), pages 211 - 22 |
| TONNELLE ET AL., EMBO J., vol. 4, no. 11, 1985, pages 2839 - 2847 |
| TOUCHMAN ET AL., GENOME RES., vol. 10, 2000, pages 165 - 173 |
| TRAIL, CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337 |
| TSE KF. ET AL., CLIN CANCER RES., vol. 12, no. 4, 15 February 2006 (2006-02-15), pages 1373 - 82 |
| TSUSHIMA, F. ET AL., ORAL ONEAL., vol. 42, 2006, pages 268 - 274 |
| TSUTSUMI M. ET AL., GENE, vol. 228, 1999, pages 43 - 49 |
| USTUN ET AL., BLOOD, vol. 118, no. 19, 2011, pages 5084 - 5095 |
| VAN DEN EYNDE B.J. ET AL., J. EXP. MED., vol. 190, 1999, pages 1793 - 1800 |
| VAN ELSAS ET AL., EXP. MED., vol. 194, no. 4, 2001, pages 481 - 489 |
| VANPOUILLE-BOX C. ET AL., NAT COMMUN, vol. 8, 2017, pages 15618 |
| VERHEIJ J.B. ET AL., AM. J. MED. GENET., vol. 108, 2002, pages 223 - 225 |
| VIRGIL EJC SCHIJNSED C LAVELLE, EXPERT REVIEW OF VACCINES, vol. 10, no. 4, 2011, pages 539 - 550 |
| VON HOEGEN ET AL., J. IMMUNOL., vol. 144, no. 12, 1990, pages 4870 - 4877 |
| VON LUKOWICZ T. ET AL., J NUCL MED., vol. 48, no. 4, April 2007 (2007-04-01), pages 582 - 7 |
| WANG ET AL., CELL RES., vol. 27, no. 1, 2017, pages 11 - 37 |
| WANG H. ET AL.: "FASEB J.", vol. 26, January 2012, SHANGHAI CANCER INSTITUTE, pages: 73 - 80 |
| WANG, S. ET AL., INT. J. CANCER, vol. 92, 2001, pages 871 - 876 |
| WEINBERG, A.D. ET AL., J IMMUNOTHER, vol. 29, 2006, pages 575 - 585 |
| WEIS J.J. ET AL., J. EXP. MED., vol. 167, 1988, pages 1047 - 1066 |
| WETERMAN M.A. ET AL., INT. J. CANCER, vol. 60, no. 1, 1995, pages 73 - 81 |
| WHITEMAN KR. ET AL., CANCER RES, vol. 72, no. 8, 15 April 2012 (2012-04-15), pages 4625 |
| WIKSTRAND CJ. ET AL., CANCER RES., vol. 55, no. 14, 15 July 1995 (1995-07-15), pages 3140 - 8 |
| WILSON ET AL., J. EXP. MED., vol. 173, 1991, pages 137 - 146 |
| WOLF P. ET AL., PROSTATE, vol. 70, no. 5, 1 April 2010 (2010-04-01), pages 562 - 9 |
| WU ET AL., NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1137 - 1145 |
| XIA M.Q. ET AL., EUR. J. IMMUNOL., vol. 21, no. 7, 1991, pages 1677 - 1684 |
| XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291 |
| XU C. ET AL., PLOS ONE, vol. 5, no. 3, 10 March 2010 (2010-03-10), pages e9625 |
| XU, M.J. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 280, no. 3, 2001, pages 768 - 775 |
| XU, X.Z. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 98, no. 17, 2001, pages 10692 - 10697 |
| YAMADA Y. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, no. 1, 1992, pages 251 - 255 |
| YAMADA,Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 195, no. 2, 1993, pages 844 - 852 |
| YAMAGUCHI, N. ET AL., BIOL. CHEM., vol. 269, no. 2, 1994, pages 805 - 808 |
| YAMAMOTO T. ET AL., NATURE, vol. 320, no. 6057, 1986, pages 230 - 234 |
| YE X. ET AL., ONCOGENE, vol. 29, no. 38, 23 September 2010 (2010-09-23), pages 5254 - 64 |
| YOVINO S. ET AL., CANCER INVEST, vol. 31, 2013, pages 140 - 144 |
| YU ET AL., INFLAMMATION, vol. 35, no. 6, 2012, pages 1773 - 1780 |
| ZALEVSKY J. ET AL., BLOOD, vol. 113, no. 16, 16 April 2009 (2009-04-16), pages 3735 - 43 |
| ZHANG J. ET AL., J DRUG TARGET., vol. 18, no. 9, November 2010 (2010-11-01), pages 675 - 8 |
| ZHANG, X. ET AL., IMMUNITY, vol. 20, 2004, pages 337 - 347 |
| ZHANGXU, J.HEMATOLOGY & ONCOLOGY, vol. 10, no. 1, 2017 |
| ZHAO X. ET AL., BLOOD, vol. 110, 2007, pages 2569 - 2577 |
| ZIMMERMAN ET AL., INTERNATIONAL IMMUNOLOGY, vol. 27, no. 1, January 2015 (2015-01-01), pages 31 - 37 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278819A (en) | Molecular adjuvant | |
| GB202010425D0 (en) | Combination vaccine | |
| GB202002166D0 (en) | Vaccine | |
| GB202020310D0 (en) | Sars-cov-2 antobodies | |
| GB202017282D0 (en) | Adjuvant composition | |
| GB202019865D0 (en) | No details | |
| GB202012321D0 (en) | No details | |
| GB202102396D0 (en) | Molecular adjuvant | |
| GB202207281D0 (en) | Vaccine | |
| GB202112149D0 (en) | Shigellla vaccine | |
| GB202016954D0 (en) | Vaccine | |
| GB202019862D0 (en) | No details | |
| GB202016370D0 (en) | Adjuvant | |
| GB201818152D0 (en) | Molecular adjuvant | |
| GB201813067D0 (en) | Molecular adjuvant | |
| HK40039229A (en) | Molecular adjuvant | |
| GB202119115D0 (en) | Vaccine | |
| GB202118110D0 (en) | Vaccine | |
| GB202114274D0 (en) | SARS-CoV-2 vaccine | |
| GB202104813D0 (en) | Sparta | |
| GB202510395D0 (en) | Vaccine | |
| GB202318238D0 (en) | Vaccine | |
| GB202102677D0 (en) | Vaccine | |
| GB202301244D0 (en) | Vaccine | |
| GB202218115D0 (en) | Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |